|
2015年职称英语卫生类教材学习部分内容及解析 Once-daily pill could simplify HIV1 treatment Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS,2 for example, are all treated with ____1____ of drugs. But that can mean a lot of pills to take. It would be ____2____ if drug companies combined all the medicines into a single pill, taken just once a day. Now, two companies say they have done that for people just ____3____ treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have ____4____ a single pill that combines three drugs currently on the market.3 Bristol-Myers Squibb sells one of them ____5____ the name of Sustiva.4 Gilead combined the ____6____, Emtriva and Viread, into a single pill in two thousand four. Combining drugs involves more than ____7____ issues. It also involves issues of competition ____8____ the drugs are made by different companies. The new once-daily pill is the result of ____9____ is described as the first joint venture agreement of its kind in the treatment of H.I.V. In January the New England Journal of Medicine5 published a study of the new pill. Researchers compared its ____10____ to6 that of the widely used combination of Sustiva and Combivir. Combivir ____11____ two drugs, AZT7 and 3TC.8 The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with ____12____ side effects.9 Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline. | 
